Expert Interview
Discussing the results from the phase III MOTION study of vimseltinib in TGCT(Tenosynovial giant cell tumor)
Ticker(s): DCPHInstitution: Mayo Clinic
- Professor of Oncology,, Chair of the Division of Community Oncology for the Department of Oncology and is Chair of the Mayo Clinic Health System Cancer Committee.
- Treats ~25 desmoid and ~10 TGCT patients.
- Research interests include the management of patients with bone and soft tissue sarcomas, as well as head and neck cancers.employing a multidisciplinary approach with surgeons and radiation oncologists.
How many TGCT patients do you treat?
Added By: wilson_adminWhat is your opinion of the data shown from vimseltinib so far?
Added By: wilson_adminHow would you rate your enthusiasm over vimseltinib on a scale of 1-10?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
